Clinical Global Impressions

News of Note

Viloxazine (Qelbree): A Faster Strattera?

Topics: ADHD Attention Deficit Hyperactivity Disorder | ADHD-RS-5 | CGI | Clinical Global Impressions | Post-hoc Analysis ADHD Rating Scale-5 | Qelbree | Viloxazine | Weiss Functional Impairment Rating Scale-Parent (WFIRS-P)

On April 2 viloxazine, brand name Qelbree, received an FDA indication for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents ages 6–17 years. Viloxazine is a norepinephrine reuptake inhibitor, similar to atomoxetine (Strattera), which was approved in 2008. Atomoxetine, while approved for ADHD, has some disadva

Read More